Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sphenopalatine ganglion block

Phase 3Small molecule

RRutgers, The State University of New Jersey

1

Indications

4

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Headache

NCT07354464

Clinical

Trials by Indication[1]

Headache3 trials

Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.

Terminated·UUniversity of Colorado, Denver·Phase 4·NCT02962427·4 enrolled

Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches

Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 3·NCT07354464·80 enrolled

Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

Terminated·RRutgers, The State University of New Jersey·Phase 3·NCT03112720·8 enrolled

Pain Management1 trial

Sphenopalatine Ganglion Block and Pain Management in Neurosurgery

Unknown status·UUniversity Hospital of Ferrara·N/A·NCT05136625·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sphenopalatine ganglion block. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sphenopalatine ganglion block compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sphenopalatine ganglion block. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rutgers, The State University of New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRutgers, The State University of New Jersey

Related News